Meet Aquaporin: The Ørestad Biotech Turning Membrane Science Into a Global Water Business

Aquaporin A/S, headquartered in the Ørestad district on the southern edge of Amager, has secured a landmark forward-purchase agreement with a Gulf desalination consortium worth an estimated €47 million over three years, according to procurement filings reviewed this week. The deal, expected to be formally announced before the end of Q3 2026, would be the largest single commercial contract in the company's nineteen-year history and the clearest signal yet that Copenhagen's bet on biomimetic membrane technology is paying off.

The timing matters. Europe is watching its water infrastructure with fresh anxiety. France logged more than 2,000 excess deaths during the June heatwave, and climate scientists at the Danish Meteorological Institute have been revising upward their projections for drought frequency across Southern and Central Europe through 2040. Water purification is no longer a niche engineering problem — it is infrastructure policy, and investors know it. Copenhagen's deep bench of life-science capital, cultivated partly through the Symbion Science Park on Fruebjergvej and the DTU Science Park in nearby Lyngby, has kept Aquaporin within reach of institutional funding even during years when the revenue line was thin.

What Aquaporin Actually Does — and Why It Took This Long

The core technology mimics the aquaporin proteins that living cells use to move water across membranes with extraordinary efficiency. Standard reverse-osmosis filtration is energy-intensive; Aquaporin's biomimetic membranes reduce energy consumption in the purification process by roughly 20 to 30 percent compared with conventional RO systems, according to technical data the company has published through the Technical University of Denmark's Department of Chemical and Biochemical Engineering. The company was spun out of DTU in 2005, which means it spent the better part of a decade in the valley of death that kills most deep-tech ventures — generating intellectual property faster than revenue.

What changed was scale and urgency. Aquaporin opened a production facility in Nørresundby, near Aalborg, in 2023, giving it manufacturing capacity that no longer depends entirely on third-party contract producers in Asia. The Ørestad office, a short Metro ride from Copenhagen Central Station on the M1 line, now houses roughly 120 employees, up from 74 at the start of 2024. The company's revenue for full-year 2025 came in at just under DKK 180 million — modest by pharma standards, but more than double the 2022 figure. A Nasdaq Copenhagen listing, discussed internally for at least two years, is understood to be contingent on the Gulf contract closing cleanly.

What the Copenhagen Tech Ecosystem Gets Out of This

The ripple effects matter beyond Aquaporin's own balance sheet. Copenhagen has been trying since at least the 2022 Copenhagen Solution launch — the municipality's ten-year digital and green-tech strategy — to position itself as a clean-tech exporter rather than merely a sustainable city. The distinction is commercial, not rhetorical: exporting technology generates tax revenue and high-wage jobs; being sustainable mostly generates good press.

The Innovation Fund Denmark, which contributed early-stage grants to Aquaporin through its InnoBooster program, has already pointed to the company in briefing materials for foreign investors visiting the Copenhagen office on H.C. Andersens Boulevard. Whether that translates into a broader funding climate for the dozen or so water and materials startups clustered around DTU and the Copenhagen Cleantech Cluster — based in Kalvebod Brygge — depends largely on how the Aquaporin story resolves over the next six months.

For readers tracking Copenhagen's tech scene, the practical advice is simple: watch the Nasdaq Copenhagen IPO pipeline in August and September, and keep an eye on the Copenhagen Cleantech Cluster's autumn cohort announcement, expected in late September. If Aquaporin closes its Gulf deal on schedule, it will almost certainly accelerate fundraising conversations for at least three or four earlier-stage companies working adjacent problems. The Ørestad biotech that nobody outside specialist circles could name two years ago may be the firm that defines the city's tech identity heading into 2027.

This article was compiled by AI and screened before publishing. See our editorial standards.